Komori
Share Issuance and Disposal9267Genky DrugStores Co.,Ltd.Retail

Notice Concerning the Issuance of Stock Options (Share Acquisition Rights)

The Company resolved to issue a total of 1,000 stock options (share acquisition rights) to 204 directors and employees of the Company and its subsidiaries. If all are exercised, 100,000 shares of the Company's common stock will be issued.

Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
100000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of stock acquisition rights as stock options

Who receives how much

100,000 shares of the Company's common stock (1,000 share acquisition rights, 100 shares per right)

The Company's internal directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries: 204 people, 1,000 rights

The lower thin line represents the existing number of shares to which these shares will be added.

The share acquisition rights will be issued free of charge. The exercise price per share will be the average closing price for each trading day in the month preceding the month in which the issue date falls, multiplied by 1.05. However, if this amount is below the closing price on the issue date, the exercise price will be the closing price on the issue date.
Terms of the stock acquisition rights
Exercise price
Average closing price for the month preceding the month in which the issue date falls × 1.05. However, if this is below the closing price on the issue date, the closing price on the issue date will apply. Adjustment provisions apply in connection with stock splits, reverse stock splits and other events, as well as to issuances below market value.
Exercise period
From 1 October 2028 through 30 September 2033 (if the final day is a holiday of the shareholder registry administrator, the preceding business day)
Number of Stock Acquisition Rights
Total number issued: 1,000 rights. Number of rights remaining unexercised: Not disclosed
Reason for acquisition without consideration
If a merger in which the Company is the disappearing company, a company split in which the Company is the splitting company, or a share exchange or share transfer in which the Company becomes a wholly owned subsidiary is approved by the General Meeting of Shareholders or the Board of Directors, the rights may be acquired free of charge on a date separately determined by the Board of Directors.
Categories and Number of Persons Covered
The Company's internal directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries: 204 people, 1,000 rights
Intended allottee's holding policy
Transfer of the stock acquisition rights requires approval from the company’s board of directors.
Basis for determining the amount to be paid
The average closing price of the Company's common stock on the Tokyo Stock Exchange for each trading day in the month preceding the month in which the issue date falls, multiplied by 1.05. If this amount is below the closing price on the issue date, the closing price on the issue date will apply (a 5% premium to the average share price).
Procedures under the Corporate Code of Conduct
Issuance based on resolutions of the 9th Annual General Meeting of Shareholders and the Board of Directors
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of stock acquisition rights as stock options
Number of shares to be issued or disposed of100,000 shares of the Company's common stock (1,000 share acquisition rights, 100 shares per right)
Issue price and disposal priceThe share acquisition rights will be issued free of charge. The exercise price per share will be the average closing price for each trading day in the month preceding the month in which the issue date falls, multiplied by 1.05. However, if this amount is below the closing price on the issue date, the exercise price will be the closing price on the issue date.
Intended allotteeThe Company's internal directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries: 204 people, 1,000 rights
Intended allottee's holding policyTransfer of the stock acquisition rights requires approval from the company’s board of directors.
Basis for determining the amount to be paidThe average closing price of the Company's common stock on the Tokyo Stock Exchange for each trading day in the month preceding the month in which the issue date falls, multiplied by 1.05. If this amount is below the closing price on the issue date, the closing price on the issue date will apply (a 5% premium to the average share price).
Exercise priceAverage closing price for the month preceding the month in which the issue date falls × 1.05. However, if this is below the closing price on the issue date, the closing price on the issue date will apply. Adjustment provisions apply in connection with stock splits, reverse stock splits and other events, as well as to issuances below market value.
Exercise periodFrom 1 October 2028 through 30 September 2033 (if the final day is a holiday of the shareholder registry administrator, the preceding business day)
Number of Stock Acquisition RightsTotal number issued: 1,000 rights. Number of rights remaining unexercised: Not disclosed
Reason for acquisition without considerationIf a merger in which the Company is the disappearing company, a company split in which the Company is the splitting company, or a share exchange or share transfer in which the Company becomes a wholly owned subsidiary is approved by the General Meeting of Shareholders or the Board of Directors, the rights may be acquired free of charge on a date separately determined by the Board of Directors.
Categories and Number of Persons CoveredThe Company's internal directors (excluding directors who are Audit and Supervisory Committee members), and directors and employees of the Company's subsidiaries: 204 people, 1,000 rights
Procedures under the Corporate Code of ConductIssuance based on resolutions of the 9th Annual General Meeting of Shareholders and the Board of Directors
Items this document does not state (16)
Total issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateDilution RateTotal number of issued sharesTransfer restriction periodConditions for lifting transfer restrictionsTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The purpose is to further enhance motivation and morale to improve the Company's consolidated performance and contribute to the expansion of its business.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Issuance of Stock Options (Share Acquisition Rights) | Genky DrugStores Co.,Ltd. (9267) timely disclosure | Komori